• Efficient GRO-seq Profiling in Wheat: Protocol Advances and

  2026-05-09

  This study presents a cost-effective and efficient protocol for GRO-seq in bread wheat, incorporating a strategic rRNA depletion step to enhance valid nascent RNA data yield. The approach demonstrates significant improvements in transcriptional profiling of complex plant genomes, offering practical benefits for plant genomics research.

• ABT-263 (Navitoclax): Applied Workflows in Cancer Biology

  2026-05-08

  ABT-263 (Navitoclax) empowers researchers to dissect apoptotic mechanisms and overcome chemoresistance in preclinical cancer models, including patient-derived rhabdomyosarcoma cells. Its nanomolar affinity and robust oral bioavailability make it an indispensable tool for apoptosis assays and combination therapy studies.

• Microglial Activation Drives Seizure Susceptibility Post-Alc

  2026-05-08

  This study reveals that acute alcohol exposure activates microglia in the hippocampus, leading to dysregulated GABAergic and glutamatergic synapse formation and heightened seizure susceptibility in mice. The findings underscore the pivotal regulatory role of microglia in neuronal circuit stability during acute neuroinflammatory insults, highlighting new research avenues for investigating seizure mechanisms.

• BMS-777607: Advanced c-Met Inhibitor for Cancer and Platelet

  2026-05-07

  BMS-777607 stands out as a powerful, selective c-Met inhibitor enabling precision targeting of MET family kinases in both cancer metastasis models and hiPSC-derived platelet production. This article translates cutting-edge protocol innovations and troubleshooting strategies into actionable workflows for translational researchers.

• Pexidartinib (PLX3397): Redefining Tumor Macrophage Modulati

  2026-05-07

  Explore how Pexidartinib (PLX3397) advances cancer research through potent CSF1R-mediated signaling inhibition and innovative macrophage modulation. This article uniquely bridges mechanistic insight and translational protocol guidance for tumor microenvironment studies.

• Aprotinin (BPTI): Reliable Inhibition for Cell Assay Precisi

  2026-05-06

  This article addresses common laboratory pain points in cell viability and cytotoxicity assays, demonstrating how Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI; SKU A2574) delivers reproducible, data-backed solutions. Drawing on real-world scenarios, peer-reviewed evidence, and protocol optimization, it offers practical guidance for biomedical researchers and lab technicians seeking robust assay performance.

• α2-AR Agonist Hydrogel Reduces Osteosarcoma Recurrence via I

  2026-05-06

  This study demonstrates that α2-adrenergic receptor agonists, delivered through a thermo-sensitive hydrogel, can significantly reduce post-surgical osteosarcoma recurrence by enhancing T cell-mediated immune rejection rather than direct cytotoxicity. The findings provide a mechanistic basis for using selective α2-AR agonists in immune modulation strategies for improved cancer management.

• Clozapine in Translational Schizophrenia: Mechanisms & Strat

  2026-05-05

  This thought-leadership article provides translational researchers with actionable insight into Clozapine’s mechanistic underpinnings, experimental strategies, and its evolving role in schizophrenia research. Integrating the latest discoveries in neuromodulation, receptor pharmacology, and signaling, it offers protocol guidance, critical comparison with noninvasive brain stimulation modalities, and forward-looking perspectives—all with direct product application and best-practice recommendations.

• Vasopressin Analogues: Expanding Utility Beyond Homeostasis

  2026-05-05

  The reference paper systematically reviews vasopressin and its analogues, highlighting the evolution from natural hormone to multitasking therapeutic peptides. It provides critical insights into the pharmacological profiles, clinical limitations, and emerging applications of analogues such as lypressin acetate, with a focus on translational potential in antidiuretic, vasopressor, and novel antiviral domains.

• Cabozantinib XL184: Mechanisms & Strategy for Translational

  2026-05-04

  This article integrates phosphoproteomic evidence and mechanistic insight to guide translational researchers deploying Cabozantinib (XL184, BMS-907351) in renal cell carcinoma (RCC) models. By dissecting timescale-dependent signaling adaptation and workflow parameters, we offer actionable strategies to maximize experimental impact and translational relevance.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC C

  2026-05-04

  This study delineates how acute versus chronic exposure to Cabozantinib (XL184) remodels phosphoproteomic signaling and cell motility in renal cell carcinoma (RCC) cells. The findings reveal timescale-dependent kinase network reprogramming, with implications for understanding resistance and adaptation to multi-kinase inhibitors in RCC.

• DFO (9H-1,8-Diazafluoren-9-one): Advanced Forensic Fingerpri

  2026-05-03

  DFO (9H-1,8-Diazafluoren-9-one) empowers forensic labs to achieve ultra-sensitive, fluorescent detection of latent fingerprints—especially on porous surfaces. This guide details real-world workflows, optimization strategies, and troubleshooting insights for maximizing visualization quality and reproducibility.

• Clozapine N-oxide: Chemogenetic Precision for Translational

  2026-05-02

  This article explores the mechanistic foundations, strategic deployment, and translational implications of Clozapine N-oxide (CNO) as a cutting-edge chemogenetic actuator. Integrating new evidence on depression circuitry and alpha-synuclein pathology, it provides actionable insights for researchers seeking targeted neuronal modulation in psychiatric and neurodegenerative models. Enhanced protocol guidance, competitive context, and a forward-looking outlook distinguish this resource from standard product literature.

• Reserpine (SKU N1867): Technical Guidance for Research Use

  2026-05-01

  Reserpine provides a high-purity tool for neurotransmitter depletion, antihypertensive mechanism studies, and neuropharmacology research workflows. Its use is restricted to laboratory-based research; it is not suitable for diagnostic or medical applications due to its potent bioactivity and handling requirements.

• EZH2 Inhibition Reduces SASP via cGAS-STING Modulation in SC

  2026-05-01

  This study uncovers how inhibition of EZH2 can mitigate the senescence-associated secretory phenotype (SASP) induced by SAHA in small cell lung cancer (SCLC) cells. By elucidating the role of the nuclear pore protein Tpr in cytoplasmic chromatin fragment (CCF) formation and subsequent cGAS-STING pathway activation, the work provides mechanistic insight with potential translational relevance for improving SCLC therapies.

15316 records 1/1022 page Next 12345 下5页 Last page